Investigating complex hormone symptoms prompts doctors to order DHEA-S blood tests to differentiate adrenal androgen activity from testicular testosterone production.
Medical Disclaimer: This article is for educational purposes only. It is not personal medical advice, a diagnostic tool, or a treatment plan. Always consult a qualified physician or endocrinologist regarding hormone testing, laboratory interpretation, and medical care.
Dehydroepiandrosterone sulfate, commonly called DHEA-S, is a circulating steroid hormone produced almost entirely by the adrenal glands. It is not a direct measurement of testicular testosterone, nor is it a universal score for male vitality, physical energy, or biological aging.
When men review comprehensive hormone panels, DHEA-S often appears alongside testosterone, free testosterone, and luteinizing hormone. Because it is chemically classified as an androgen, many assume it reflects testicular health or explains common symptoms such as fatigue or low libido. In clinical medicine, DHEA-S serves a different purpose. It acts as an adrenal biomarker that helps physicians evaluate adrenal cortex activity, investigate potential steroid excess, and gather clues about adrenal function.
This guide provides an in-depth breakdown of DHEA-S physiology, how it differs from testicular androgens, what laboratory reference ranges mean across the lifespan, and how clinicians interpret abnormal results.
To understand DHEA-S, one must first look at how the body organizes steroid hormone production. The adrenal glands sit atop the kidneys and are divided into distinct layers. The outer region, known as the adrenal cortex, contains three specialized zones that synthesize different classes of hormones.
The outermost zone produces mineralocorticoids such as aldosterone to balance sodium and potassium. The middle zone synthesizes glucocorticoids, primarily cortisol, to regulate metabolism, immune activity, and stress responses. The innermost layer, known as the zona reticularis, is the primary manufacturing site for adrenal androgens, including dehydroepiandrosterone (DHEA) and its sulfated counterpart (DHEA-S).
In the adrenal cortex, cholesterol undergoes enzymatic modifications to become pregnenolone. Pregnenolone is subsequently converted into DHEA through the action of the enzyme 17-alpha-hydroxylase. Once DHEA is formed, a sulfotransferase enzyme attaches a sulfate group to the molecule, transforming it into DHEA-S.
This chemical sulfation changes how the molecule behaves in the bloodstream:
According to medical research published in Endotext, circulating DHEA-S levels are approximately 300 times higher than free DHEA concentrations in healthy adults. Because DHEA-S is stable and abundant, clinical laboratories measure DHEA-S rather than free DHEA when assessing adrenal androgen production.
By itself, DHEA-S possesses relatively weak androgenic potency. It binds to androgen receptors with only a fraction of the affinity demonstrated by testosterone or dihydrotestosterone (DHT). However, circulating DHEA-S acts as an endocrine and intracrine substrate. Various peripheral tissues, such as the skin, adipose tissue, prostate, and liver, absorb DHEA-S, remove the sulfate group, and convert it locally into more active androgens or estrogens.
One of the most frequent misconceptions in male hormonal health is equating DHEA-S with testosterone. While both molecules are androgens, their anatomical origin, physiological regulation, and clinical implications are entirely distinct.
In healthy adult men, steroid production is divided between two primary axes: the hypothalamic-pituitary-gonadal (HPG) axis and the hypothalamic-pituitary-adrenal (HPA) axis.
The hypothalamus releases gonadotropin-releasing hormone (GnRH), which prompts the pituitary gland to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Luteinizing hormone travels to the testes, where it stimulates Leydig cells to synthesize testosterone. The testes produce roughly 5 to 7 milligrams of testosterone each day, accounting for over 95 percent of all circulating testosterone in adult males. This testicular production is responsible for primary male secondary sexual characteristics, deep voice, facial hair, sperm maturation, and systemic androgenic tone.
The hypothalamus releases corticotropin-releasing hormone (CRH), triggering the pituitary to release adrenocorticotropic hormone (ACTH). ACTH acts upon the adrenal cortex to stimulate both cortisol and adrenal androgens like DHEA and DHEA-S. While some peripheral tissues convert adrenal androstenedione and DHEA into testosterone, research in Endotext confirms that this pathway contributes less than 5 percent of total testosterone production in adult men.
The physiological differences between these two hormones can be summarized through four key attributes:
Clinical guidelines from the Government of British Columbia on hormone testing emphasize this biological separation. The guidance explicitly states that DHEA-S is not useful for investigating male hypogonadism because it is an adrenal steroid.
When a man experiences low libido, muscle loss, or erectile difficulties, testing DHEA-S will not clarify whether his testes are functioning properly. A man can have normal or elevated DHEA-S alongside clinically low testosterone if his testicular function is impaired. Conversely, a man with primary adrenal insufficiency may have low DHEA-S while maintaining normal testicular testosterone production. Readers seeking to understand gonadal function should review testosterone fundamentals and hormonal function rather than relying on adrenal markers.
When clinicians evaluate complex endocrine cases, they rarely look at DHEA-S in isolation. Instead, they interpret it as one component within a broader network of steroid hormones and regulatory proteins. Understanding how DHEA-S relates to other key markers provides necessary context for laboratory reviews.
Total testosterone measures all circulating testosterone in the blood, including hormone bound to proteins and unbound hormone. In adult men, it serves as the foundational test for identifying hypogonadism. Because total testosterone reflects testicular Leydig cell output, it answers questions about gonadal health that DHEA-S cannot address.
Sex hormone-binding globulin (SHBG) is a carrier protein produced by the liver that binds tightly to testosterone and estradiol. Testosterone that is not bound to SHBG is either loosely attached to albumin or completely unbound (free). DHEA-S binds weakly to albumin and does not bind meaningfully to SHBG. As a result, fluctuations in SHBG levels alter free testosterone concentrations dramatically while leaving DHEA-S dynamics largely unaffected. Readers exploring these relationships can learn more in our detailed section on testing and biomarkers.
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are pituitary gonadotropins. In men with low total testosterone, LH and FSH determine whether the root cause is primary (testicular failure) or secondary (pituitary or hypothalamic suppression). These gonadotropins regulate the testes, not the adrenal glands. Therefore, an abnormal LH level points directly to the gonadal axis, whereas an abnormal DHEA-S level points toward the adrenal axis.
Cortisol is the primary glucocorticoid synthesized in the adrenal cortex under the direction of adrenocorticotropic hormone (ACTH). Because ACTH stimulates both cortisol and DHEA-S synthesis in the adrenal gland, evaluating cortisol alongside DHEA-S helps clinicians assess overall adrenal cortex health. In suspected adrenal insufficiency or pituitary dysfunction, paired testing of cortisol, ACTH, and DHEA-S provides a clearer clinical picture.
Prolactin is a pituitary hormone that can suppress gonadotropin secretion when present in excessive amounts (hyperprolactinemia). Prolactin screening is common when investigating secondary hypogonadism, low libido, or pituitary adenomas. While prolactin does not directly regulate DHEA-S, pituitary disorders can simultaneously affect prolactin output and ACTH secretion, indirectly influencing adrenal steroid production.
Because DHEA-S is an adrenal biomarker, physicians order it when investigating specific clinical questions involving the adrenal cortex, abnormal androgen production, or structural adrenal findings. It is not intended as a routine screening test for general wellness.
When a patient presents with signs of abnormal steroidogenesis, clinicians measure DHEA-S to determine if the adrenal cortex is overproducing androgens. In adult men, severe androgen excess can originate from congenital adrenal hyperplasia (CAH), a group of genetic enzyme deficiencies that impair cortisol synthesis and divert steroid pathways toward adrenal androgens.
Marked elevations in DHEA-S can also raise clinical suspicion for androgen-secreting adrenal cortical carcinomas or adenomas. While these tumors are rare, a significantly elevated DHEA-S level prompts further imaging and specialized endocrine workups.
With the widespread use of abdominal CT and MRI scans for unrelated complaints, radiologists frequently discover asymptomatic adrenal nodules, known as adrenal incidentalomas. Endocrine guidelines published in the European Journal of Endocrinology recommend evaluating all adrenal incidentalomas for hormonal activity.
Measuring DHEA-S, alongside overnight dexamethasone suppression testing and plasma metanephrines, helps determine if the mass is biologically active. In some adrenal carcinomas, autonomous overproduction of DHEA-S is the primary biochemical signature. Conversely, certain cortisol-producing adenomas may suppress pituitary ACTH, leading to low DHEA-S in the non-tumorous adrenal tissue.
Adrenal insufficiency occurs when the adrenal glands fail to produce adequate amounts of essential steroid hormones, particularly cortisol. It can be primary, caused by direct damage to the adrenal cortex (such as autoimmune Addison disease), or secondary, caused by pituitary failure to secrete ACTH.
When diagnosing adrenal insufficiency, the standard diagnostic tools are morning serum cortisol levels, plasma ACTH, and the cosyntropin (synthetic ACTH) stimulation test. However, research in Endotext and the European Journal of Endocrinology highlights that low DHEA-S for age and sex can serve as a valuable supportive clue. Because the zona reticularis is vulnerable to cortical atrophy, a subnormal DHEA-S concentration supports the suspicion of adrenal impairment, though it is never diagnostic on its own.
In complex diagnostic cases involving ambiguous steroid levels or mixed clinical features, measuring both testicular hormones and DHEA-S helps isolate the anatomical source of the disturbance. If androgen excess is present, an elevated DHEA-S points toward an adrenal origin, whereas an elevated testosterone with normal DHEA-S suggests a gonadal or hypothalamic-pituitary source.
Interpreting a DHEA-S result requires understanding its dramatic age-related trajectory. Unlike some biomarkers that remain relatively constant throughout adult life, DHEA-S follows a distinct curve characterized by a sharp rise during puberty and a steady, progressive decline across middle and older age.
During childhood, DHEA-S production is minimal. Around ages six to eight, a maturation process known as adrenarche begins in the adrenal cortex, initiating DHEA-S synthesis. Blood concentrations climb steeply through adolescence, reaching their lifetime peak between ages 20 and 30.
Following this peak, circulating DHEA-S concentrations decrease by roughly 1 to 2 percent per year. Research on adrenal androgens and aging published in Endotext notes that the steepest decline occurs between ages 20 to 30 and 50 to 60. By age 70 to 80, circulating DHEA-S concentrations in men often fall to 10 to 20 percent of young adult values.
Because of this physiological trajectory, a DHEA-S value cannot be interpreted without knowing the patient's exact age and the specific reference interval used by the performing laboratory.
MedlinePlus provides the following typical reference ranges for male DHEA-S across different age brackets:
These intervals are illustrative ranges provided by MedlinePlus. Reference standards vary between commercial testing facilities due to differences in assay platforms, calibration methods, and reference populations. A patient should always evaluate their results against the reference range printed directly on their official laboratory report.
Comparing an older man's DHEA-S result against a young-adult reference range creates false alarms. A concentration of 85 µg/dL is completely normal for a 58-year-old man, even though that same value would fall below the expected threshold for a 22-year-old.
When a DHEA-S blood test returns below the laboratory reference interval, clinicians must interpret the finding in light of the patient's medical history, current medications, and presenting symptoms. A low DHEA-S value is not a standalone diagnosis of disease.
As discussed, adrenal androgen synthesis naturally decreases over decades. In many cases, a low value simply reflects normal biological aging. If a man in his fifties or sixties exhibits a low DHEA-S level but has normal morning cortisol, normal testicular testosterone, and no systemic symptoms of adrenal crisis, the finding is generally considered a benign physiological variation.
Exogenous glucocorticoid medications, such as prednisone, dexamethasone, hydrocortisone, or high-dose inhaled steroids, are among the most common causes of low DHEA-S. Glucocorticoids exert negative feedback on the hypothalamus and pituitary gland, suppressing the release of CRH and ACTH. Deprived of ACTH stimulation, the adrenal zona reticularis reduces DHEA-S production. This suppression can persist for months after stopping the medication.
In primary adrenal insufficiency (Addison disease), autoimmune destruction, infection, or vascular damage harms the adrenal cortex. Because the zona reticularis is damaged alongside the zona fasciculata, DHEA-S levels frequently drop near zero. In secondary adrenal insufficiency, pituitary tumors, head trauma, or surgery reduce ACTH output, leading to adrenal atrophy and low DHEA-S.
While a low DHEA-S level increases clinical suspicion for adrenal failure, Endotext explicitly notes that it is never diagnostic on its own. Diagnosis requires formal assessment of cortisol output, typically through early-morning serum cortisol and an ACTH stimulation test.
Broad pituitary gland dysfunction, known as hypopituitarism, affects multiple endocrine axes simultaneously. If the pituitary fails to produce ACTH, thyroid-stimulating hormone (TSH), LH, and FSH, a patient may present with concurrent low DHEA-S, central hypothyroidism, and central hypogonadism.
An elevated DHEA-S level indicates that the adrenal cortex is producing androgens at a rate exceeding normal reference parameters for age and sex. Because DHEA-S is cleared slowly, persistent elevations point toward distinct clinical states that warrant professional investigation.
Congenital adrenal hyperplasia refers to inherited enzymatic defects in steroid synthesis, most commonly 21-hydroxylase deficiency. When the adrenal cortex cannot efficiently convert steroid precursors into cortisol, the pituitary senses the cortisol deficiency and secretes high amounts of ACTH. Constant ACTH stimulation drives the adrenal cortex to overproduce adrenal androgens, leading to markedly elevated DHEA and DHEA-S. While classic CAH is identified in infancy, non-classic or late-onset CAH may present later with mild hormonal abnormalities.
Adrenal adenomas (benign) and adrenal cortical carcinomas (malignant) can autonomously synthesize steroid hormones independent of pituitary ACTH regulation. When an adrenal tumor overexpresses steroidogenic enzymes, circulating DHEA-S can rise to extreme levels. In clinical practice, an unexpectedly high DHEA-S level in an adult male prompts an abdominal imaging evaluation to rule out structural adrenal lesions, as outlined in MedlinePlus medical reviews.
DHEA is available as an over-the-counter dietary supplement in several countries. When men take oral DHEA supplements, the liver and intestines rapidly sulfate the compound into DHEA-S, causing serum DHEA-S levels to surge well above physiological reference ranges. Clinicians evaluating an elevated result must always review the patient's full supplement and medication history before initiating extensive imaging or laboratory investigations.
When reviewing information about DHEA-S, it is vital to distinguish between established endocrine consensus and preliminary, unproven claims. The medical literature displays clear boundaries regarding what DHEA-S testing can and cannot accomplish.
Robust, peer-reviewed medical guidance from major endocrine organizations supports the following uses:
In recent decades, epidemiological research has examined the correlation between declining DHEA-S concentrations and various age-related health outcomes. Observational studies have noted associations between low DHEA-S and reduced bone mineral density, shifts in body composition, cardiovascular markers, and self-reported well-being in aging populations.
However, observational association does not establish causation. While circulating DHEA-S declines as humans age, research has not proven that this decline causes aging or that raising DHEA-S reverses physiological changes. Controlled clinical trials evaluating DHEA administration in older men have yielded mixed and modest results, failing to demonstrate consistent improvements in physical strength, cognitive function, or sexual performance.
Commercial wellness marketing frequently misrepresents DHEA-S as a youth hormone, an energy index, or an adrenal fatigue score. Terminology such as adrenal fatigue is not recognized by mainstream endocrinology, as noted in clinical reviews from the Mayo Clinic.
Using a DHEA-S blood test as a general rating of vitality, sexual prowess, or biological age is scientifically unsupported. Interpreting laboratory results through such lenses often leads to inappropriate self-supplementation, unnecessary anxiety, and failure to investigate valid medical causes for symptoms. Readers wanting a deeper look at male hormone science can review our articles on testosterone basics.
The clinical meaning of a DHEA-S result depends heavily on the reason the test was ordered, the patient's age, and other concurrent lab values. The following illustrative patterns show how physicians analyze real-world endocrine results.
A 42-year-old man visits his physician reporting persistent fatigue, reduced exercise recovery, and low sexual desire. A comprehensive laboratory panel reveals:
Clinical Interpretation: The patient's symptoms correlate directly with low total and free testosterone. His normal DHEA-S confirms that adrenal androgen production is healthy and intact. This demonstrates why DHEA-S cannot diagnose hypogonadism; the adrenal cortex is functioning properly, but the gonadal axis is suppressed. The physician focuses the workup on the hypothalamic-pituitary-gonadal pathway rather than the adrenal glands. Readers can learn more about symptoms in our section on low testosterone.
A 64-year-old man receives a routine health panel and notices his DHEA-S is flagged as low on an online patient portal:
Clinical Interpretation: When compared against the laboratory's age-stratified reference range for men over 60 (less than 204 µg/dL), the patient's value of 75 µg/dL is entirely normal. His normal morning cortisol rules out adrenal crisis. The initial concern was solely the result of comparing an older adult's result against young-adult reference data. No treatment or further adrenal imaging is required.
A 38-year-old man managing asthma with daily high-dose inhaled corticosteroids undergoes a broad hormone evaluation:
Clinical Interpretation: The low DHEA-S and borderline-low cortisol are expected physiological consequences of corticosteroid exposure. Exogenous steroids suppress pituitary ACTH secretion, reducing adrenal cortex stimulation. The physician recognizes that this is an iatrogenic effect rather than primary Addison disease. The clinical plan focuses on reviewing medication dosing with the patient's pulmonologist rather than ordering unnecessary adrenal biopsies.
A 52-year-old man undergoes an abdominal CT scan following a minor traffic accident, revealing a 2.5-centimeter mass on his left adrenal gland. His follow-up biochemical evaluation shows:
Clinical Interpretation: The significantly elevated DHEA-S confirms that the adrenal mass is biologically active and actively synthesizing adrenal androgens. The normal metanephrines rule out a pheochromocytoma, and normal urinary cortisol rules out Cushing syndrome. The patient is referred to an endocrine surgeon and an endocrinologist for specialized management of an androgen-secreting adrenal cortical neoplasm.
A 34-year-old man presents with progressive weakness, orthostatic lightheadedness, unexplained weight loss, and hyperpigmentation of the knuckles:
Clinical Interpretation: While a morning cortisol of 5.1 µg/dL is ambiguous on its own, the severely suppressed DHEA-S serves as a strong supportive clue of cortical failure. The physician immediately orders a standard high-dose ACTH stimulation test and checks plasma ACTH and adrenal autoantibodies. The testing confirms primary autoimmune adrenal insufficiency, allowing the patient to begin essential glucocorticoid and mineralocorticoid replacement therapy.
If your recent blood tests included DHEA-S, having a focused, evidence-based conversation with your healthcare provider will ensure the results are interpreted accurately. Here are practical questions to guide your discussion:
In healthy adult men with normal testicular function, oral DHEA supplementation rarely produces meaningful or reliable increases in circulating testosterone. Because men already produce ample testosterone directly in the testes, the liver rapidly converts supplemental DHEA into DHEA-S, downstream estrogens, or minor metabolites.
Randomized controlled trials show that DHEA supplementation in men primarily increases circulating DHEA-S and estrogen levels with negligible impacts on muscle mass or free testosterone.
Unlike total testosterone and cortisol, which follow steep diurnal rhythms and must be drawn in the early morning, DHEA-S has a half-life of 16 to 24 hours and maintains stable circulating concentrations throughout the day. While fasting is often requested if other biomarkers (such as glucose, lipids, or morning cortisol) are being measured simultaneously, DHEA-S itself does not strictly require an early morning or fasted sample. However, following your laboratory's standard testing protocol ensures consistency.
Acute stress activates the hypothalamic-pituitary-adrenal axis, triggering ACTH release that temporarily stimulates both cortisol and adrenal androgen synthesis. However, chronic psychological stress does not reliably elevate DHEA-S over the long term.
In many cases of chronic physiological stress or severe illness, the adrenal glands shift steroid synthesis preferentially toward cortisol at the expense of adrenal androgens. A markedly elevated DHEA-S level should never be dismissed simply as everyday stress and warrants proper clinical evaluation.
DHEA-S is not used to monitor or adjust testosterone replacement therapy. TRT acts upon the hypothalamic-pituitary-gonadal axis and suppresses testicular testosterone production, while DHEA-S is regulated independently by the adrenal axis.
Physicians monitor TRT using total testosterone, free testosterone, estradiol, hematocrit, and PSA. DHEA-S levels typically remain unchanged during TRT unless the patient is taking separate adrenal medications. For more information on hormone therapy research, explore our guides on TRT and emerging research.
Testostra explains testosterone biology, testing, symptoms, lifestyle factors and TRT with careful sourcing and clear clinical limits.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra
